Kidney Cancer: Symptoms, Diagnosis and Treatment
Kidney cancer in adults most commonly means renal cell carcinoma (RCC). Many renal cancers are now found incidentally on ultrasound or CT performed for another reason, before symptoms develop. When symptoms occur, they can include blood in the urine, persistent flank discomfort, a palpable mass, weight loss or anaemia, but these are not specific to cancer. A suspicious renal mass is usually characterized with contrast-enhanced CT or MRI. For localized disease, surgery is often curative, and partial nephrectomy is preferred when it can remove the tumour safely while preserving kidney tissue. Some small renal masses can be monitored or treated with ablation. Metastatic RCC is treated mainly with systemic combinations such as immunotherapy and targeted therapy, with surgery used selectively.
What is renal cell carcinoma?
RCC arises from kidney tubular cells. Clear-cell RCC is the most common subtype, followed by papillary and chromophobe RCC, with several rarer entities. Subtype and grade affect prognosis and systemic-treatment choices. Cancer arising from the renal pelvis is usually urothelial carcinoma and is managed differently from RCC.
Symptoms and how kidney cancer is found
- Incidental renal mass on ultrasound, CT or MRI — now the most common presentation.
- Visible or microscopic blood in urine.
- Persistent flank pain or pressure.
- Palpable abdominal mass, usually in more advanced disease.
- Unexplained weight loss, fever, fatigue or anaemia.
- Less commonly, symptoms from metastatic disease such as bone pain or cough.
How is a renal mass evaluated?
Ultrasound can detect a mass but often cannot fully characterize it. A renal-mass protocol CT or MRI assesses whether the lesion enhances with contrast, whether it is solid or cystic, its size and relationship to vessels/collecting system, and whether there are suspicious lymph nodes or venous extension. Kidney function is checked before treatment planning.
Do all kidney masses need biopsy?
No. Imaging can be sufficiently characteristic that a localized enhancing mass proceeds directly to surgery in selected patients. Renal-mass biopsy is useful when the result will change management — for example before ablation, when lymphoma/metastasis/infection is possible, or when deciding between surveillance and intervention. A non-diagnostic biopsy does not prove a mass is benign.
Treatment of localized kidney cancer
| Option | When it is used | Main consideration |
|---|---|---|
| Partial nephrectomy | Preferred for many T1 tumours and whenever kidney preservation is important and technically feasible | Removes tumour with a margin while preserving the rest of the kidney. |
| Radical nephrectomy | Large/complex tumours not safely amenable to partial nephrectomy or when oncologically appropriate | Removes the entire kidney, often with surrounding fat; adrenal gland is not routinely removed unless involved/suspicious. |
| Active surveillance | Selected small renal masses, older/frail patients or those with major competing health risks | Uses serial imaging; intervention is considered if growth or risk changes. |
| Thermal ablation | Selected small tumours, especially when surgery carries higher risk | Cryoablation or thermal techniques destroy tumour; biopsy is usually obtained and follow-up imaging is essential. |
Why partial nephrectomy is important
When technically safe, partial nephrectomy preserves nephrons and reduces loss of kidney function without compromising cancer control for many small localized tumours. Complexity depends on tumour size, depth, location near the collecting system or vessels, and whether the patient has one kidney or pre-existing kidney disease.
What about metastatic kidney cancer?
Modern metastatic RCC treatment uses immune-checkpoint inhibitors, VEGF-targeted tyrosine-kinase inhibitors and other targeted agents in combinations chosen according to tumour subtype, risk and previous therapy. Cytoreductive nephrectomy is no longer automatic for every metastatic patient; it is used selectively when disease distribution, symptoms and response to systemic therapy make surgery advantageous.
Hereditary kidney cancer
Genetic assessment should be considered when kidney cancer occurs at a young age, is bilateral or multifocal, has suggestive histology, or there is a strong family history. Hereditary syndromes can change surveillance thresholds, timing of surgery and screening recommendations for relatives.
Follow-up after treatment
Surveillance is risk-based and includes imaging for recurrence, creatinine/eGFR and blood-pressure monitoring. After partial or radical nephrectomy, preserving long-term kidney health is part of cancer survivorship: avoid unnecessary nephrotoxic drugs, control diabetes/BP and address cardiovascular risk.
When to seek urgent care
Heavy haematuria with clots or urinary retention, severe flank pain with fever, fainting, or new severe symptoms after surgery require urgent assessment. New neurological symptoms in a patient with metastatic disease also warrant emergency evaluation.
How kidney cancer is staged and graded
Stage describes anatomic extent. A tumour confined to the kidney is staged mainly by size: T1 is up to 7 cm and T2 is larger than 7 cm while still confined to the kidney. T3 includes extension into major veins or tissues around the kidney without going beyond Gerota’s fascia, while T4 extends beyond that fascial envelope or into the ipsilateral adrenal gland by direct invasion. Lymph-node and distant-metastasis findings complete the TNM stage.
Grade is a microscopic estimate of aggressiveness. For clear-cell and papillary RCC, WHO/ISUP nucleolar grade is commonly used. Grade and stage are different: a small high-grade cancer can merit closer follow-up than a similar-sized low-grade tumour. Histological subtype, tumour necrosis, sarcomatoid/rhabdoid features and margin status can also affect prognosis.
Choosing between surveillance, ablation and surgery for a small renal mass
Not every small enhancing mass must be removed immediately. Active surveillance can be reasonable for older or medically frail patients and for selected small tumours where competing health risks are greater than the near-term cancer risk. Surveillance means planned repeat imaging, not ignoring the lesion. Tumour growth, size, imaging appearance, biopsy findings when obtained and patient health are reassessed over time.
Thermal ablation can treat selected small peripheral tumours with less invasive recovery, but local recurrence or retreatment risk can be higher than after excision and tissue diagnosis is usually obtained. Partial nephrectomy remains the reference surgical option for many T1 tumours when technically feasible because it removes the lesion while preserving renal tissue. Radical nephrectomy is appropriate when partial nephrectomy would be unsafe, leave inadequate kidney tissue or compromise cancer clearance.
Recovery and life after kidney surgery
After minimally invasive partial or radical nephrectomy, walking and oral intake usually resume early, while fatigue and abdominal discomfort improve over the following weeks. Heavy lifting is restricted during initial healing. After partial nephrectomy, bleeding or urine leak are uncommon but important complications; after any kidney surgery, fever, worsening flank/abdominal pain, fainting or new heavy haematuria should prompt urgent assessment.
Long-term kidney health matters even after the cancer is cured. Blood pressure, diabetes, smoking, obesity and unnecessary nephrotoxic medicines can influence the remaining renal function. Patients with reduced eGFR, a solitary kidney or significant proteinuria may benefit from nephrology input in addition to cancer surveillance.
What the kidney pathology report adds after surgery
After partial or radical nephrectomy, pathology confirms the tumour subtype, size, grade and pathological stage and reports whether the surgical margin is involved. It may also describe necrosis, sarcomatoid or rhabdoid change and invasion of veins, renal sinus or surrounding fat. These details refine recurrence risk and determine the intensity of surveillance. In selected higher-risk clear-cell RCC, adjuvant systemic therapy may be discussed after complete resection; this is a specialist decision based on pathological risk, fitness and the balance between potential benefit and treatment toxicity.
Systemic treatment for advanced kidney cancer is different from chemotherapy for many other cancers
Conventional cytotoxic chemotherapy has a limited role in the common clear-cell renal cell carcinoma. Modern systemic treatment mainly uses immune checkpoint inhibitors and drugs that block angiogenesis/VEGF signalling, often in combination. The exact regimen depends on histology, disease burden, symptoms, risk group, previous treatment, autoimmune disease, kidney/liver function and drug access.
For selected patients with a few metastatic sites, surgery or stereotactic radiotherapy may still be used as part of a broader plan. For patients with high-risk clear-cell RCC after complete nephrectomy, adjuvant pembrolizumab can be discussed in appropriately selected patients; it is not needed for every kidney cancer removed by surgery.
Consultation checklist
- Ultrasound, CT and MRI reports plus actual images.
- Creatinine/eGFR and urine tests.
- Previous renal surgery or biopsy reports.
- Blood-pressure, diabetes and kidney-disease history.
- Family history of kidney cancer or known hereditary syndrome.
- Current medicines, especially blood thinners and nephrotoxic drugs.
- If metastatic: complete systemic-treatment timeline and latest staging scans.
FAQs
Is every kidney mass cancer?
No. Benign tumours such as oncocytoma and fat-poor angiomyolipoma can mimic RCC, and many cysts are benign.
Does a kidney tumour always require removal of the whole kidney?
No. Partial nephrectomy is preferred for many localized small tumours when technically feasible.
Can kidney cancer be cured?
Localized RCC is often cured with surgery. Prognosis depends on stage, grade, subtype and other pathological features.
Does kidney cancer respond to chemotherapy?
Traditional cytotoxic chemotherapy has a limited role in most RCC. Modern systemic treatment relies mainly on immunotherapy and targeted agents.
Can I live normally with one kidney?
Many people do, but kidney function, blood pressure and long-term cardiovascular/renal health should be monitored, especially if baseline kidney disease exists.
Does every high-risk kidney cancer need immunotherapy after surgery?
No. Adjuvant pembrolizumab is considered for selected higher-risk clear-cell RCC after complete resection. Many patients are cured by surgery alone and should not receive systemic treatment without a clear risk-benefit discussion.
Related reading
- Renal Mass on Ultrasound: What Next?
- Small Renal Mass Explained
- Renal Cyst vs Kidney Cancer
- Bosniak Classification Explained
- Uro-Oncology Second Opinion: When Should You Take One?
- Kidney Cancer Stage Explained
- Immunotherapy for Kidney Cancer
- Targeted Therapy for Kidney Cancer
- Urologist in Latur
References
- European Association of Urology (EAU). EAU Guidelines on Renal Cell Carcinoma. 2026 edition https://uroweb.org/guidelines/renal-cell-carcinoma
- National Cancer Institute. Renal Cell Cancer Treatment (PDQ®)–Patient Version https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq
- American Urological Association. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up Guideline (2017; amended 2021) https://www.auanet.org/guidelines-and-quality/guidelines/renal-mass-and-localized-renal-cancer-evaluation-management-and-follow-up
- Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385:683-694; subsequent overall-survival update.